Investment Rating - The industry investment rating is "Overweight" indicating a positive outlook for the high-value medical consumables sector [1]. Core Insights - The sixth batch of national centralized procurement for high-value medical consumables was held on January 13, 2026, with 12 types of medical consumables included, resulting in 440 products from 202 companies being selected [1]. - The selection rules were optimized to ensure that clinically recognized and capable products were chosen, emphasizing a "de-involution" approach [2]. - The report highlights the long-term growth potential of the high-value consumables sector post-price reduction expectations, driven by an aging population and increasing surgical and diagnostic volumes [2]. Summary by Sections Procurement Results - The procurement included drug-coated balloons and urological intervention consumables, with a high selection rate: all 42 products from 32 companies in the drug-coated balloon category were selected, and 398 products from 170 companies in the urological intervention category were chosen [2]. - Specific products with unique functions were also selected, meeting clinical needs [2]. Selection Rules - The selection process ensured that products with high clinical recognition and strong supply capabilities were prioritized [2]. - A pricing mechanism was introduced to reflect clinical value, avoiding a simple lowest-price selection method [2]. Company Analysis - Key companies involved include Lepu Medical, MicroPort Medical, and others, with notable price reductions in selected products compared to previous procurements [2]. - The report suggests monitoring companies such as Lepu Medical, MicroPort Medical, and others for investment opportunities [2]. Valuation Table - A valuation table is provided, showing market capitalization and projected profits for various companies, indicating their financial performance and P/E ratios for 2026 and 2027 [3].

Core Insights - The sixth batch of centralized procurement results for high-value medical consumables has been announced, including 12 types of medical consumables from two categories: drug-coated balloons and urological intervention materials [1] - A total of 227 companies submitted 496 products for bidding, with 202 companies and 440 products selected for procurement, indicating a diverse supply from mainstream companies [1] - The procurement aims to stabilize clinical use, ensure quality, and prevent price undercutting, with a focus on matching clinical needs and maintaining supply capabilities [2][3] Industry Overview - The procurement includes drug-coated balloons, which are used to treat vascular stenosis, and urological intervention materials, which were previously a "blank area" in centralized procurement [2] - The selection process reflects principles of stability in clinical use, quality assurance, and prevention of excessive competition, ensuring that products with high clinical recognition and strong supply capabilities are chosen [2][3] Company Implications - Leading domestic companies are expected to benefit from the procurement results, with several listed companies among those selected [4] - Companies like Lepu Medical and Xianruida have announced that their products have been fully selected, with specific pricing details provided for various drug-coated balloon products [4] - The procurement is anticipated to provide opportunities for domestic companies to expand their market share, despite potential short-term profit margin impacts due to price reductions [5]

Group 1 - The sixth batch of national organized high-value medical consumables centralized procurement has been conducted, resulting in selected products from 202 companies out of 227 that submitted bids, covering 12 types of medical consumables [1] - Drug-coated balloons, which improve vascular stenosis by expanding blood vessels and releasing medication, have been included in the procurement, with all 42 products from 32 companies selected, ensuring high clinical compatibility while reducing patient costs [1] - Urological intervention consumables, previously a "blank area" in procurement, saw 398 products from 170 companies selected, addressing the needs for various surgical procedures related to kidney and ureteral stones [1] Group 2 - Since 2020, the healthcare insurance department has conducted six batches of centralized procurement, successfully acquiring 142 types of medical consumables across nine major clinical fields, including cardiology, orthopedics, and urology [2] - The results of the procurement will be officially announced soon, with implementation expected around May 2026, allowing patients access to high-quality and affordable selected products [2]

Core Insights - The sixth batch of centralized procurement for high-value medical consumables was held in Tianjin, resulting in the selection of 440 products from 202 companies out of 496 bids from 227 companies, indicating a diverse supply of products to meet clinical needs [1][2] Group 1: Procurement Details - The procurement includes 12 types of medical consumables, specifically drug-coated balloons and urological intervention materials, which are crucial for treating vascular and urinary conditions [1] - All 42 products from 32 companies in the drug-coated balloon category were selected, ensuring a high match with clinical usage while reducing patient costs [1] - In the urological intervention category, 398 products from 170 companies were selected, addressing a previously unaddressed area in centralized procurement [1] Group 2: Policy Implementation - The procurement aligns with the central government's policy to optimize procurement processes, emphasizing stability in clinical use, quality assurance, and prevention of price undercutting [2] - Group competition was implemented to ensure continuity in clinical usage, with products selected based on demand and supply capabilities [2] - The selection rules were optimized to prevent price undercutting, with a benchmark set at 65% of the average price when the lowest bid is excessively low, impacting 8 out of 20 competitive groups [2] Group 3: Historical Context - Since 2020, the healthcare insurance department has conducted six batches of centralized procurement, successfully acquiring 142 types of medical consumables across various clinical fields, including cardiology, orthopedics, and urology [2]